In this paper we consider the effects of a single anticancer agent on the growth of a solid tumour in the context of a simple mathematical model for the latter. The tumour is assumed to comprise a single cell population which reproduces and dies at a rate dependent on the local drug concentration. This causes cell movement and so establishes a velocity field within the tumour. We investigate the action of a single chemotherapeutic drug on the tumour and explore how different drug kinetics and treatment regimes may affect the final treatment outcome. A single infusion of drug is shown to be more effective than repeated short applications. We are able to construct asymptotic solutions to the model in the limit of a small drug degradation rate; these closely match solutions obtained numerically and provide additional insight into the behaviour of the tumour, in particular allowing the prediction of the strength of drug required to achieve tumour regression.
Introduction
Cancer chemotherapy involves the use of drugs to disrupt the cell cycle and so block proliferation. The success of chemotherapeutic agents varies widely, depending on cell type and the type of drug being used. The effectiveness of a particular drug is dependent on the concentration of drug reaching the tumour, the duration of exposure and the sensitivity of the tumour cells to the drug. Multicellular spheroids (MCSs) are routinely used as in vitro models of cancer growth. This is due to their structural similarity to solid tumours and the ease with which they can be controlled in the laboratory [1] . Anticancer agents are tested on MCSs in order to gain insight into their effectiveness.
Given the obvious importance of cancer treatment, comparatively little modelling work has been carried out on the response of tumours to chemotherapy. Furthermore, mathematical models of chemotherapy generally ignore spatial effects, focussing instead on the time-dependent evolution of the total cell number. For example, in a series of papers by Murray [2] [3] [4] , optimisation techniques are used with the aim of minimising tumour burden while maintaining a normal cell population above a given threshold level. Costa et al. [5] also use such techniques to model response to treatment. An alternative approach which does incorporate spatial effects is to use cellular automata to simulate threedimensional growth and treatment [6, 7] . Other, more recent work includes that in [8] in which a model of tumour growth is analysed which includes angiogenesis and lymphangiogenesis (the formation of new lymph vessels).
Models that do consider spatial effects are generally based on the assumption that tumours are spherically symmetric. For example, Wein et al. [9] use a mathematical model of the spatio-temporal dynamics of brain tumours to study the effects of a specific cytotoxic agent and Jackson and Byrne [10] study the effects of drug resistance and vasculature on treatment. The continuum model of tumour growth presented in [11] is extended in [12] to include chemotherapy. The response of monolayers and spheroids is compared and multicellular spheroids are shown to display enhanced survival rates compared with monolayers, a result which is consistent with experimental observations.
Presented in this paper is a model similar to that of [11] , but simplified, allowing significantly more analytical insight than in [12] . The tumour is modelled as a continuum, the processes of proliferation and death, together with an assumption of incompressibility, causing cell movement and so establishing a velocity field within the tumour. The version of this growth model we that adopt here is the simplest possible, allowing the effects of a chemotherapeutic drug to be investigated in as transparent a framework as possible. The drug is assumed to travel via diffusion and to degrade at a rate proportional to its rate of uptake by the tumour cells. Previous chemotherapy models have assumed the kinetics of drug uptake to take one of two forms, linear and saturable [5, 13] . In this paper we compare the effects of different drug kinetics on treatment (see also [12] ) and show that experimental results [14] obtained from in vitro experiments can be replicated. Using the insight gained from the numerical solutions, we then adopt assumptions which make the model analytically tractable. By doing this we are able to find a condition which predicts whether the treatment will be successful. Moreover, if treatment is unsuccessful, then we are able to obtain information about the growth rate and spatial structure of the tumour. The results given here are described in somewhat greater detail in [15] .
Model derivation

Model formulation
We consider a nutrient-rich solid avascular tumour composed of a single type of cell, whose concentration is denoted by n(r, t). The tumour may expand or contract depending on the net rate of cell growth, which in turn depends on the local concentration of a chemotherapeutic drug which kills tumour cells in a dose-dependent manner. We assume that the transition from the live to the dead state causes a spontaneous volume loss. The processes of proliferation and death, combined with an assumption of incompressibility, cause cell movement and so establish a velocity field, v(r, t), within the tumour. We neglect the effect of any externally supplied nutrients, assuming instead that, in the absence of the drug, all cells proliferate at a constant rate k n (corresponding to the early stages of avascular growth and to a highly idealised model for the growth of a well-vascularised tumour). We thus do not include an explicit cell death term (in other words, either negligible death occurs or k n denotes the net proliferation rate in the absence of the drug, i.e. cell proliferation rate − cell death rate, if the dead material can be taken to disappear instantaneously on the timescale of tumour growth; see below). We investigate the effect of a single chemotherapeutic drug on the tumour and denote the concentration of this drug by w(r, t). The equation governing the cell concentration, n, is then given by
where κ(w) describes the rate of cell death due to exposure to the drug and is specified below. Because we are assuming the tumour to be incompressible and to consist of one cell type (e.g. the products of cell death are assumed to be rapidly absorbed by, or lost from, the tumour) we have
where V L is the average volume of a single live cell, so that n is constant. Substituting (2) into Eq. (1) gives
which states that the local volume change is given by the difference between the rates of cell volume increase, k n , and decrease, κ(w).
The drug is assumed to diffuse into the tumour with constant diffusion coefficient, D w , and to degrade at a rate proportional to its rate of uptake by the cells. The drug may also be advected by the cells, with velocity v(r, t). These assumptions lead to the following partial differential equation for w:
where the positive constant α gives a measure of the rate of cell kill relative to the rate of drug degradation. We investigate two functional forms for κ(w) (linear and Michaelis-Menten kinetics) in order to compare the action of different drugs on the tumour. When treating spheroids, cell survival often either decreases approximately linearly with increasing drug concentration, or decreases until a critical drug concentration is reached beyond which there is negligible further decrease in survival [16] . To model these observations we choose (in a similar way to [12] ) the following functional forms of κ(w):
where µ is a measure of the effectiveness of the drug, w 0 is the maximum external drug concentration and k d is a 'critical' drug concentration. Cases (i) linear kinetics and (ii) Michaelis-Menten kinetics result in different behaviours of κ(w) and can therefore be expected to produce different qualitative results. We assume the tumour to be spherically symmetric, so that time, t, and radial distance from the centre of the tumour, r , are the only independent variables. This assumption means that (3) determines the velocity field without the need to impose a constitutive law. Under radial symmetry, our model thus reads
where Eq. (9) simply states that the tumour boundary, r = S(t), moves with the local cell velocity. To complete the system we impose the following initial and boundary conditions:
where r 0 is the initial radius of the tumour, w 0 is the external drug concentration and W (t) describes the drug regime being used. Possible drug regimes are continuous infusion and a series of bolus injections. 1 The latter is more common clinically as it reduces the toxic effects of the drug on the patient. However, it is worth comparing the two regimes for several reasons. Experimentalists tend to look at the effects of continuous application in vitro, so we are more likely to find experimental data with which to assess our findings. Whilst, at present, continuous infusion tends not to be a suitable drug delivery method due to the toxic effects of these chemicals, drugs (and methods of drug delivery) are extensively being sought which specifically target cells within the tumour rather than normal cells, making continuous infusion a more viable option (see [17] [18] [19] for example).
Nondimensionalisation
We now nondimensionalise the governing equations. Denoting dimensionless variables by * we adopt the rescalings:
where k 0 is a typical cell proliferation rate under ideal conditions (i.e. where nutrient supply and space are freely available so that cell proliferation proceeds unhindered). Under these scalings Eqs. (7)- (9) become
where β = k 0 r 2 0 /D w and α * = D w αw 0 V L /k 0 r 2 0 are dimensionless parameters. In practice, we estimate β = O(10 −6 ) (see Appendix A and [12] ), and hence adopt the quasi-steady approximation given in Eq. (15) . This approach has been used by several other authors when modelling nutrient concentration (e.g. [20] [21] [22] ) and, since the diffusion coefficients for nutrients and many chemotherapeutic drugs are similar (again, see Appendix A), an equivalent approach also applies here, giving
The scalings imply that κ(w * ) becomes
The transformed versions of the initial and boundary conditions defined in (10) are
For the remainder of the paper, the * 's are dropped except in Appendix A, where quantities without * 's are dimensional.
The timescale is such that t = 1 represents about 46 h and the length scale is such that S = 1 represents about 20 µm (see Appendix A). The size of multicellular spheroid used in experiments varies, with diameters tending to be in the range 200-1200 µm [23] . We note that if the tumour is untreated, so that w = 0, then the system of Eqs. (12) and (14)- (17) can be solved explicitly to give
Thus the tumour volume grows exponentially for all time, corresponding to the initial stage of avascular growth (and pertinent to vascular growth), and the velocity increases linearly with r . 
Numerical results
Preamble
In this section we use the numerical methods described in Appendix B to illustrate how a growing tumour may respond to treatment. By comparing the results from our simulations with experimental ones we are able to obtain estimates of parameter values which are not directly available from the literature.
Unless stated otherwise, the tumour is allowed to grow untreated until it reaches the size S = 20 (which occurs at t s ≈ 8.9) and then treatment is commenced so that
Parameter estimation
While some of the model parameters can be estimated from results available in the literature (see Appendix A), others cannot. In particular, and to our knowledge, values for α have not been reported. In this section we replicate a set of experimental results in order to obtain an estimate for this important parameter. Fig. 1 shows how the surviving fraction of cells (defined as the ratio of the current cell population to the cell population at the start of the treatment period) at times t = 0.02, t = 0.06 and t = 0.1 (equivalent to dimensional times 1, 3 and 5 h) varies with the externally prescribed drug concentration when µ = 30 and k n = 1 using Michaelis-Menten kinetics. For this simulation, we start treatment when S = 6.25 so that we can compare our results directly with those in experimental papers [14] .
From the results presented in Fig. 1 , it can be seen that for small fixed drug concentrations the fraction of surviving cells decreases rapidly over time, but as the drug concentration increases, the fraction of surviving cells tends to a limit which depends only on the time since the start of treatment. These results are qualitatively similar to those obtained in experimental work on multicellular spheroids [14] . The spheroids used in these experiments were approximately 250 µm in diameter, which is small enough that spatial variation of nutrient concentration through the tumour need not be substantial (the viable rim thickness is usually in the range 120-280 µm; see [24] ), in keeping with our model (where nutrient is assumed to be readily available). The results are also comparable with those in [25] . Several sets of simulations were performed with different parameter values in order to find those which gave the closest match to the experimental data (which was presented in the same form as that shown in Fig. 1 ). The ones chosen for use in the rest of this section (obtained by visual comparison with the results of [14] ) are
Referring to Appendix A and the rescalings given in (11), the equivalent dimensional values are µ = 180 × 10 −6 s −1 , k n = 6 × 10 −6 s −1 , α = 24 × 10 10 mlg −1 cm −3 and k d = 2 × 10 −6 gml −1 . Fig. 1 we plot the drug concentration profile within the tumour at t = 9, shortly after the initiation of treatment.
Comparison of drug kinetics
Here we compare the effects of the two types of kinetics (linear and Michaelis-Menten) on tumour growth. In Fig. 2 we do this for different values of the drug effectiveness parameter, µ. When µ is sufficiently small (e.g. µ = 1), neither type of drug is effective enough to cause tumour regression. It can be seen that the drug with linear kinetics is more potent than the one governed by Michaelis-Menten kinetics. This is also true for large µ (e.g. µ = 10), though the difference between the two is less pronounced.
The interplay between cell kill (due to the drug) and drug degradation is not entirely straightforward. We illustrate this in Fig. 3 where we have plotted the drug concentration at t = 9 ( just after the initiation of treatment) for each of the simulations shown in Fig. 2 . For small µ, drug penetration is slightly better under Michaelis-Menten kinetics. However, for larger µ the reverse is true, though we note that magnifying the region nearest the tumour boundary shows that at the rim of the tumour the drug concentration is lower when using linear kinetics. These effects are due to the forms of the two kinetic terms. For high drug concentrations the proportion of cells killed is higher when using linear kinetics, leading to a greater rate of degradation; for low drug concentrations the reverse is true, the crossover between the two being dependent on the value of k d .
In Fig. 4 we investigate how changes in the size of the tumour at the start of treatment affect drug penetration and the internal velocity when using Michaelis-Menten kinetics. For very small tumours, a high concentration of drug penetrates almost uniformly throughout the tumour. However, as the size of the tumour increases, the drug penetration depth decreases (relative to the tumour size), leading to a rapid decline in drug concentration from its maximum at the boundary to a negligible amount at the centre (see Fig. 4(a) ). From Fig. 4(b) we can also see that, for small tumours, drug penetration at high concentrations is sufficient to ensure that the rate of cell death is greater than the proliferation rate throughout the tumour and hence the cell velocity is negative everywhere. However, for large tumours cell death dominates only in the outer rim of the tumour, with cell proliferation effectively unrestricted in the centre. Because of the continuous supply of drug on the boundary, the cell velocity there is always negative for the parameter values chosen. At points within the tumour at which the concentration of drug is below a critical value (given by w = k n /µ for linear kinetics and w = k n k d /(µ − k n ) for Michaelis-Menten kinetics, from Eq. (12)), the rate of drug-induced cell death is outweighed by the rate at which additional cells are being created by proliferation and so the cell velocity there is positive.
Treatment regimes
We now investigate the way in which different treatment protocols affect the outcome. Because of the inherent toxicity of anticancer drugs to normal cells, treatment regimes usually involve a series of short infusions rather than a prolonged period of continuous application (the former regime gives normal cells time to recover). Drug infusion times vary widely depending on the drug being used and on the geographical place of treatment (drug regimes vary from country to country and even between hospitals in the same country). For example, when using Taxol (a cyclespecific agent used in the treatment of breast and ovarian cancer), infusion times range from 1 to 96 h, with the most common treatment being one with a period of 21 days and an infusion time of 3 h [26, 27] .
In Fig. 5 , we compare two different drug regimes to see how they affect the growth of the tumour. The tumour is allowed to grow without restriction until its radius reaches the dimensionless size S = 60 (this is equivalent to approximately 1200 µm in diameter). We have chosen a large tumour size for this simulation in order to exaggerate the difference between the two regimens. The drug is then given either continuously for one time period (and then removed), or as a series of five shorter doses of equal length, the total treatment time (equal to 0.5 units) and dose being the same for each regimen. A continuous application of the drug is seen to be more effective than giving repeat bolus injections. This is because between each bolus application the tumour cells are able to proliferate without restriction, so the overall effect is lessened. It should be noted, however, that in a clinical setting the continuous infusion method is unlikely to be the most appropriate as, with the drugs currently available, it could prove to be dangerously toxic to the patient due to its impact on healthy tissues. The results shown in Fig. 5 are similar to those of tumour cell level in the ordinary differential equation model of [3] , who considered a similar chemotherapy regime.
4. Small drug degradation rate, α 1
Introduction
In this section we investigate the outcome of constant, continuous exposure of the tumour to a drug in order to determine situations in which all the cells will be killed and the tumour eliminated. Guided by the results shown in Fig. 4 we consider two main timescales, the first being t = O(1), where w = O(1) throughout the tumour, and the second having t = O(ln α), where w 1 in the centre of the tumour. On the second timescale, a rapid decrease in drug concentration inwards from the tumour boundary is caused by its absorption by cells nearer the boundary, a boundary layer forming at the rim of the tumour. In this case we construct solutions in the outer rim and inner core and use matched asymptotics to construct the full solution.
The governing equations are (12), (14)- (16) subject to (17) and we take W (t) = 1, so that at r = S, w = 1, corresponding to continuous exposure to drug. We note that it follows from these that
a simplification which we have not used in the numerics because it does not extend to more general models (which will be the subject of later papers). From (15), we have
where
at r = S, w = 1,
as our moving boundary problem. Except for the k n S/3 term, this is mathematically equivalent for constant κ to a reverse Hele-Shaw squeeze film problem (albeit in three dimensions). The radial solutions to the multidimensional versions of the latter are known to be unstable, which suggests that instabilities are likely also to arise in the current problem. An analysis of these is beyond the scope of the current paper, however, particularly since their exploration would require the introduction of constitutive assumptions regarding the mechanical properties of the tumour. Throughout this section the asymptotic results will be compared with the numerical simulations of the full system of equations with α = 500, k n = 1, k d = 0.2 and, unless otherwise stated, we take µ = 30. In the analysis for the second timescale we shall introduce an artificial (large-time) small parameter.
Initial behaviour, t = O(1)
During the initial stages of growth, the tumour is small enough that the drug concentration is approximately spatially uniform (see Fig. 4 ). In our numerical simulations we used large values of α and we now exploit this asymptotically, expanding the dependent variables v, w and S in powers of 1/α such that
Substituting these expansions into Eqs. (12), (14) and (15) and equating the leading order and first-order correction terms gives
where the indicates differentiation with respect to the first argument, e.g. v 0 (S 0 , t) = ∂v 0 /∂r at r = S 0 , and κ (w 0 ) = dκ/dw at w = w 0 . The initial and boundary conditions are:
Eqs. (26)- (29) can easily be solved to give
where S 0 = exp((k n − κ(1))t/3). Thus in order to reduce the tumour size we require, as anticipated from (12), k n < κ (1) . Recalling the definition of κ(w) stated in Eq. (5), we deduce that the bifurcation between tumour growth and regression occurs when µ = k n (1 + k d ) (for Michaelis-Menten kinetics) and µ = k n (for linear kinetics). Hence we are able to predict the strength of drug required to cause tumour regression. If the condition for regression is not met then the drug will not induce a sufficiently high level of cell death even on the tumour boundary, and so the treatment will fail. The above asymptotic expansion ceases to be valid when the correction terms becomes comparable in magnitude as the leading order term. For example, in Eq. (30) the expansion breaks down when
This will occur when t = 3 ln α/2(k n − κ(1)) + O(1). The results presented in Fig. 6 demonstrate the good agreement between our numerical simulations and our asymptotic solution for drugs whose behaviour is governed by Michaelis-Menten kinetics. As µ increases, the length of time for which the analytical solution matches the numerical result increases. The reason for this is that for high values of µ, the tumour takes a long time to become large enough for the constant w approximation to become invalid. For values of µ that give rise to tumour regression, the analysis is valid for all t. Similar results emerge when the drug and velocity profiles are compared.
Long-term behaviour
We now discuss the long-term behaviour of (12), (14) and (15) when the treatment is unsuccessful. Following the early timescale analysis of Section 4.2, we observe that the tumour grows large and the drug concentration ceases to be almost uniform. This situation arises if either the drug is not very effective (i.e. κ(1) < k n ) or if the drug is not administered until the tumour has become large. We scale α out of the system using the transformations t = 3 ln α/2(k n − κ(1)) + T, r = α 1/2 R, S = α 1/2S , v = α 1/2 V . Then Eqs. (12), (14) and (15) 
We are unable to solve these equations (they represent a full balance) in their current form but we are able to investigate the long time limit, T → ∞. Guided by the numerical results shown in Fig. 4 we anticipate that in this limit there are two regions to be analysed: (a) a central core in which w 1 and (b) an outer rim in which w = O(1). Taking the limitS → ∞, we use the method of matched asymptotic expansions to match the two regions (we remark that this structure applies for large time for any α). We focus on the long-time behaviour by making the rescalings V =V / , R =R/ andS =Ŝ/ , where 0 < 1 is an artificial small parameter. Under these rescalings Eqs. (34)- (36) 
We now construct solutions in the core and rim of the spheroid.
(a) The core We first writeV and w in terms of aŝ
Substituting these into Eqs. (37)- (39) gives the following expressions for the leading order and first-order correction terms for V and w:
where as before κ (w 0 ) = dκ/dw at w = w 0 . We are able to solve these equations usingV (0, T ) = 0 to give
and the drug concentration is zero to all orders (i.e. exponentially small) throughout the core, with cell growth there occurring as in the untreated case.
(b) The viable rim In order to focus on the rim region we translate Eqs. (37)- (39) usingR =Ŝ + z, so fixing the spheroid surface at z = 0 (note that z → −∞ as we match onto the core). We then write
By substituting (45) into (37)- (39), and equating the leading order and first-order correction terms we find
From (46) and (48) it is easy to show that
where we have matched with the core solution to determineV 0 , and D 0 is some constant which is dependent on the earlier evolution (corresponding to a shift in the origin of T ). The fact that ∂ŵ 0 /∂z is a function of z only is a consequence of the analysis that follows, but for convenience we shall assume this henceforth. Using Eq. (49) together with Eqs. (46) and (48) it is possible to show that
where we have matched with the core solution. Using Eqs. (48), (49) and (51) it can then be shown that
where D 1 is another constant dependent on the earlier evolution. Combining the above results we deduce that
In order to find expressions forŵ 0 and its first derivative with respect to z we must consider separately the two functional forms for κ(ŵ).
Case (i) -Linear Kinetics
In this case we know from the first of (47) that
and as z → −∞, w 0 → 0.
Hence,ŵ 0 = exp( √ µz). In Fig. 7 we demonstrate that the good agreement between the numerical solution of the full problem and the longtime analytical solution (with D = 0.07). We note that the large tumour radius (S = 350,000 ≡ 7 m) will not occur in practice. In Fig. 8 we show how both the long-and short-time asymptotic expansions provide good approximations to the numerical solution of the full problem on the timescales for which they are valid.
Case (ii) -Michaelis-Menten Kinetics
In this case the first of (47) subject to (57) gives, on integrating once,
This equation can be integrated numerically to give the drug profile in the rim. The correction term satisfies the second of (47). Fig. 9 shows how the short-and long-time asymptotic results match the numerical results in the timescales for which they are valid when using Michaelis-Menten kinetics. 
Linear kinetics and steady-state analysis
For κ(w) = µw we have from (15) and (17) that
So, by (22) 
and hence, by (14) , the problem reduces to the ordinary differential equation
We did not exploit this reduction above because it does not of course generalise to the more interesting Michaelis-Menten case with which we wished to make comparison. Focussing now on continuous infusion, W (t) = 1, we have
so that
Thus for µ < k n we have Θ(S) > 0 for all S > 0, as anticipated, and hence
for some constant S ∞ that will depend on the initial data (i.e. on the tumour size at the start of treatment). For µ > k n , however, we have an unstable steady state S = S c , determined as the unique positive solution to Θ(S c ) = 0; though unstable, this plays an important borderline role in that the treatment will be unsuccessful if S > S c holds when it starts, leading to the large-time behaviour (66), while if S < S c initially then the tumour will be eradicated, with
where the constant S ∞ again depends on the initial data. Qualitatively, much of this behaviour goes over to the Michaelis-Menten case (and indeed to general drug kinetics); (66) is unchanged, while the factor µ−k n in (67) is replaced by µ/(k d +1)−k n , since w ∼ 1 holds uniformly across a shrinking tumour as t → ∞. Using (22) , the (unstable) steady-state size S c is to be determined from the free boundary value problem
at r = S c , w = 1,
Such bifurcation behaviour is also to be expected when the drug kinetics κ(w) in (12) and (15) are made distinct, though the associated free boundary problem is then more complex. Substantial analytical progression on the moving boundary problem (23)- (25) is also possible for
corresponding in particular to Michaelis-Menten kinetics with negligible k d . For S < (6α/µ) 1/2 we then have
where R(t) and S(t) are given by
It follows in particular that the critical radii for µ > k n , R c and S c , are given by
We again remark on the close correspondence between aspects of (71), which implies the continuity conditions
and recent modelling (e.g. [28] and references therein) of negative squeeze films. This reinforces the point that the multidimensional versions of such formulations are likely to have interesting properties, with the associated fingering instabilities in turn having potentially important therapeutic implications.
Discussion
In this paper we have presented a simple mathematical model of tumour growth in which the spheroid is treated as a continuum of cells. A velocity field is generated by the volume changes that accompany cell birth and death. We have assumed that all cells proliferate at a constant rate (independently of oxygen or other nutrients) and we have not included a spontaneous cell death term. Uptake by the cells of a single diffusible chemotherapeutic drug is the only mechanism by which cell death can occur. The drug-free tumour growth model captures the initial exponential phase of tumour growth. It can be used to replicate results obtained experimentally for small, well-oxygenated tumours [14] . By comparing different drug delivery protocols we have also shown that continuous drug infusion is more effective than repeated bolus applications, consistent with predictions made by [29] using a simple spatially averaged ODE model.
In our model, the tumour cells react instantaneously to the local concentration of drug. This (together with the quasi-steady assumption for the drug concentration) means that once treatment is stopped the drug is instantaneously removed from the tumour and exponential growth resumes immediately. In practice, a period of several days [30] elapses before regrowth commences. This is presumably largely due to the cells taking time to re-enter the growth phases of the cell cycle after treatment ceases.
For cases in which the rate of drug degradation is small we were able to construct asymptotic approximations which are in good agreement with our numerical results of the full model. We are able to find simple conditions (dependent on the relationship between the cell proliferation rate, in particular, and the effectiveness of the drug) for the complete eradication of the tumour. We were also able to predict the tumour's growth rate when the drug is not strong enough for regression to occur. In summary, we have been able to show that if k n > κ(1) ultimately the tumour grows exponentially. Further, if k n < κ(1) then there are three possibilities. An unstable steady state may occur, where the tumour radius is given by S c . If the tumour radius is larger than this at the start of treatment then exponential growth occurs. If the tumour radius is smaller than S c at the start of treatment then S → 0 as t → ∞.
There is considerable scope for further work based on the model presented in this paper. An obvious extension to the model is to include a nutrient, as previously done by [11] . Another option for extending the model is to include the phenomenon of drug resistance. Mathematical models exist for all the major forms of cancer treatment (notably radiotherapy, chemotherapy and gene therapy). However, few of these use a spatio-temporal model of tumour growth. Extending our model to include drug resistance would therefore be potentially valuable. Finally, the use of models that describe the cell cycle would potentially be a useful tool in obtaining information regarding the mechanisms used by different drugs to kill cells; see for example [31, 32] . Such model extensions will be described in future papers; see also [15] .
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Appendix A. Parameter values
In this appendix, all parameters are given as dimensional quantities unless otherwise stated. While the volume of experimental literature is large, very little of it includes relevant parameter values, especially with respect to drug action kinetics, in part because parameters vary widely with the cell line used and the experimental procedure. Cell diameters are in the range 10-100 µm [33] , with a cell concentration of approximately 5 × 10 8 cells cm −3 [34, 35] . Cell cycle times can range from 11 h to 5 days [36, 37] .
Drug diffusion rates vary depending on the size of the drug molecules and the permeability of the surrounding tissue. Measurements for tumours in 2% agar solution vary in the range 1.1-15 × 10 −6 cm s −1 [38] .
Values of w 0 , the drug concentration on the tumour boundary, can be estimated from concentrations used in experiments involving tumour spheroids growth in vitro. Concentrations used in experiments vary in the range 0.05-20 µg ml −1 [30, [39] [40] [41] [42] and so we have chosen our basic parameter value to be 10 µg ml −1 unless otherwise stated.
The values of k d and α have been estimated by comparing the results of extensive numerical simulations with the experimental results of [14] in which a series of experiments were performed on spheroids to determine how the drug dosage affects the surviving fraction of cells after different exposure times. Table 1 gives the parameter estimates chosen for simulations which are used throughout this paper.
Appendix B. Numerical methods
In order to solve numerically the moving boundary problem presented in this paper, we make the coordinate transformation r = S(t)ρ, so that ρ lies on the unit interval. The rescaled system can then be written as 
We solve Eqs. (80)-(83) using finite difference approximations in the following way. We split the (ρ, t)-plane into a spatially non-uniform grid. For large S, the rescaling concentrates the region of most variation into a boundary layer at the outside edge of the tumour, a contracting mesh being used. Grid points ρ = ρ i are prescribed by ρ i = ρ i−1 (1 − c) + c, 1 < i < I (i.e. ρ i = 1 − (1 − c) i−1 ), where I is the number of mesh points in the radial direction and c (<1) is a constant chosen so that the gap between each consecutive pair of mesh points is smaller than the previous pair and the data points near the centre of the tumour are close enough together that variations there are adequately captured. Grid points t = t j are defined by t j = ( j − 1) t, 1 < j < J , where J − 1 is the number of time steps; i.e. the time step is uniform. We define v(ρ i , t j ) = v i, j , w(ρ i , t j ) = w i, j and S(t j ) = S j .
Following [43] , we use a predictor-corrector method to determine S, v and w. Denoting predicted and corrected (updated) values by the superscripts p and u respectively, we first predict a value of S using the formula 
where ρ i+1/2 = (ρ i+1 + ρ i )/2, with the suffix notation for w defined similarly. We solve Eq. (81) using the Numerical Algorithm Group (NAG) routine D02RAF which approximates the partial differential equation by using finite difference techniques and solves the resulting equations with a combination of Newton iteration and a deferred correction technique. The finite difference equations are set up on our predefined mesh and estimates of the solution at each mesh point are chosen using the results from the previous time step. These initial values are then used as starting values for the Newton iteration. The accuracy of the solution can be improved by deferred corrections and/or by adding more points to the mesh. We then use the predicted values of S, v and w to update S using the trapezium method to approximate (82), so that 
Finally we update v and w using the same methods as in the predictor step, before moving on to the next time step and repeating the predictor-corrector method. The use of a single corrector step follows [43] and at each time step the difference between S p − S u was found to be no more than 10 −3 (for t = 0.001, the time step used in simulations).
